Cancer Cell - September 12, 2022

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy 

Zhang, Rohweder et al report that covalent K-Ras(G12C) inhibitors can lead to the presentation of drug-modified neoantigens by class I MHC. A bispecific T cell engager that recognizes these neoantigens elicits a cytotoxic T cell response against KRas G12C cells, including those resistant to direct KRasG12C inhibition.

Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity

William A. Freed-Pastor,  Andrew J. Aguirre - Cancer Cell Preview 

Featured Articles and Interviews 

Closing in on Cancer's Deadliest Mutations - nature Feature Article

Developing A Drug To Identify And Target Tricky Cancer Cells - Discover Magazine

The scientist who pioneered kras drugs has a new idea about making them more powerful - Endpoints News

Drug Turns Cancer Gene Into “Eat Me” Flag for Immune System - UCSF News

KGO810 The Pat Thurston Show - Charles Craik interview - Stitcher   Apple Podcast

The epic battle with cancer's 'Death Star' - The Guardian

Ziyang Zhang - Chemical biology champion is toppling drug targets with novel approaches - c&en

Kevan Shokat interviewed "Drugging the undruggable" - Disease Models and Mechanisms on YouTube

Patent Cooperation Treaty (PCT) filing - Patentscope